InsiderClue
Stocks · Health care · Pharmaceutical Preparations

TuHURA Biosciences, Inc./NV

HURA Clue Score33
United States Fiscal year ends December CIK 0001498382
$1.90 -3.06% Close, 12 Oct 2026
Alert on the numbers Alert on insider trades
Price $1.90 +98.74% Close, 12 Oct 2026

Closing prices at the end of each trading day, from 13 Oct 2016. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueNet income
Fiscal year 2018Net income11.1Fiscal year 2019Net income−8.0 −172.3%Fiscal year 2020Net income−9.1Fiscal year 2021Net income−38.3Fiscal year 2022Net income−22.7Fiscal year 2023Net income−14.6Fiscal year 2023Revenue0.0Net income−29.3EPS, diluted−2.47Fiscal year 2024Net income−8.3Fiscal year 2024Revenue0.0Net income−21.7EPS, diluted−1.21Fiscal year 2025Revenue0.0Net income−30.1EPS, diluted−0.63
FY2018FY2019FY2020FY2021FY2022FY2023FY2023FY2024FY2024FY2025
Revenue n/a n/a n/a n/a n/a n/a 0.0 n/a 0.0 0.0
Growth
Net income 11.1 −8.0 −9.1 −38.3 −22.7 −14.6 −29.3 −8.3 −21.7 −30.1
Growth −172.3%
EPS, diluted n/a n/a n/a n/a n/a n/a −2.47 n/a −1.21 −0.63

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2018Operating cash flow−9.9Fiscal year 2019Operating cash flow−6.3Fiscal year 2020Operating cash flow−7.9Fiscal year 2021Operating cash flow−18.9Fiscal year 2022Operating cash flow−20.4Fiscal year 2023Operating cash flow−11.9Fiscal year 2023Operating cash flow−12.0Capital expenditure−0.1Free cash flow−12.0Buybacks−0.0Fiscal year 2024Operating cash flow−7.2Fiscal year 2024Operating cash flow−14.7Capital expenditure−0.1Free cash flow−14.8Fiscal year 2025Operating cash flow−27.6Capital expenditure−0.1Free cash flow−27.7
FY2018FY2019FY2020FY2021FY2022FY2023FY2023FY2024FY2024FY2025
Operating cash flow −9.9 −6.3 −7.9 −18.9 −20.4 −11.9 −12.0 −7.2 −14.7 −27.6
Capital expenditure n/a n/a n/a n/a n/a n/a −0.1 n/a −0.1 −0.1
Free cash flow n/a n/a n/a n/a n/a n/a −12.0 n/a −14.8 −27.7
Growth
Buybacks n/a n/a n/a n/a n/a n/a −0.0 n/a n/a n/a

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2018Cash6.0Total debt0.0Net cash (debt)6.0Shareholders’ equity5.4Debt to equity0.00Fiscal year 2019Cash3.7Shareholders’ equity2.0Fiscal year 2020Cash2.4Shareholders’ equity0.3Fiscal year 2021Cash10.5Shareholders’ equity10.6Fiscal year 2022Cash11.8Shareholders’ equity11.8Fiscal year 2023Cash1.5Shareholders’ equity0.7Fiscal year 2023Cash3.7Shareholders’ equity−1.6Fiscal year 2024Cash4.9Shareholders’ equity3.8Fiscal year 2024Cash12.7Shareholders’ equity14.6Fiscal year 2025Cash3.6Shareholders’ equity20.9
FY2018FY2019FY2020FY2021FY2022FY2023FY2023FY2024FY2024FY2025
Cash 6.0 3.7 2.4 10.5 11.8 1.5 3.7 4.9 12.7 3.6
Total debt 0.0 n/a n/a n/a n/a n/a n/a n/a n/a n/a
Net cash (debt) 6.0 n/a n/a n/a n/a n/a n/a n/a n/a n/a
Shareholders’ equity 5.4 2.0 0.3 10.6 11.8 0.7 −1.6 3.8 14.6 20.9
Debt to equity 0.00 n/a n/a n/a n/a n/a n/a n/a n/a n/a

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2017 30 Jun 2017 FY2018 30 Jun 2018 FY2019 30 Jun 2019 FY2020 30 Jun 2020 FY2021 30 Jun 2021 FY2022 30 Jun 2022 FY2023 30 Jun 2023 FY2023 31 Dec 2023 FY2024 30 Jun 2024 FY2024† 31 Dec 2024 FY2025† 31 Dec 2025
Revenue and profit
n/a n/a n/a n/a n/a n/a n/a 0.0 n/a 0.0 0.0
Growth
−5.0 −7.1 3.7 3.6 11.8 15.2 9.3 9.4 2.7 13.3 20.5
−3.3 −4.0 4.7 4.5 9.8 7.5 5.5 4.1 5.8 3.9 7.6
n/a n/a n/a n/a n/a n/a n/a 29.3 n/a −21.7 −30.1
n/a n/a n/a n/a n/a n/a n/a 0.0 n/a 0.0 0.0
8.1 11.1 −8.0 −9.1 −38.3 −22.7 −14.6 −29.3 −8.3 −21.7 −30.1
Growth +37.8% −172.3%
Per share
0.74 5.42 3.16 −0.87 −1.60 −25.80 −9.27 −2.47 −0.32 −1.21 −0.63
n/a n/a n/a n/a n/a n/a n/a −2.47 n/a −1.21 −0.63
Growth
12.0 2.1 2.6 10.4 25.9 1.0 1.6 11.9 26.4 18.7 47.9
n/a n/a n/a n/a n/a n/a n/a 11.9 n/a 18.7 47.9
Growth +156.8%

† The diluted share count jumps at 2024 and 2025, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 9 of 11 years on file.